Uppsala, Sweden – Strike Pharma, the company using its proprietary Adaptable Drug Affinity Conjugate (ADAC™) technology platform to develop individualized immunotherapeutic treatments, today announced the appointment of Joacim Elmén M.Sc., Ph.D. as Director, Chemistry, Manufacturing, and Controls (CMC). As a member of the Strike Pharma team, Joacim will have overall responsibility for the development and manufacture of GMP-compliant products to be used in clinical trials.

Tina Furebring, Commercial Operations Officer at Strike Pharma commented, “We are extremely pleased to welcome Joacim to Strike Pharma. With his extensive experience in similar capacities, most recently as Director CMC at Affibody AB, he will play a key role in our efforts to take ADAC technology to the clinic.”

Beginning with a M.Sc. in Chemical Engineering from Royal Institute of Technology (KTH), Stockholm and a Ph.D. in Medical Science from the world-renowned Karolinska Institute in Stockholm, Joacim has, over more than 15 years, held senior positions in well-recognized biopharmaceutical companies including Cobra Biologics and Santaris Pharma (now part of Roche).

Mårten Winge, CEO of Strike Pharma added, “With the key competence that Joacim brings to the team, Strike Pharma is now empowered with the top-level management experience and skills needed to deliver on our goals. All steps we take now are aimed at taking us closer to demonstrating what ADAC technology can achieve in the clinic.”

Today, Strike Pharma is focused on the development of clinically-relevant candidates for use as immunotherapeutics for the treatment of solid tumors. By using ADAC technology, novel treatments can be generated based on the genetic profiles from tumor biopsies. Such highly targeted treatment offers the potential to increase therapeutic efficacy and reduce dosage levels, thereby minimizing the risk of side effects.


About Strike Pharma (www.strikepharma.com)

Headquartered in Uppsala, Sweden, Strike Pharma is using the company’s proprietary Adaptable Drug Affinity Conjugate (ADAC) technology to take precision medicine to a new level, enabling development of truly individualized immunotherapeutic treatments based on the genetic profile of each patient’s tumor. Such highly targeted treatment offers the potential to not only increase therapeutic efficacy, but also to reduce dosage levels thereby minimizing the risk of side effects.

Today, Strike Pharma’s development program is focused on selection of novel, clinically-relevant candidates for use as immunotherapeutic treatment of solid tumors. However, the company is confident that the ADAC technology platform has the potential to facilitate development of many other antibody-based therapeutics and that this novel approach will have a significant impact across a wide variety of disease indications within the rapidly developing field of personalized medicine.

Strike Pharma was founded in 2020 with the aim of commercializing ADAC technology. Investors include Eir Ventures, Flerie Invest, Uppsala University Invest, Almi Invest, SLU Invest and Monesi Förvaltnings.


Mårten Winge CEO

+46 (0) 70 657 59 27

[email protected]